Cargando…

Sarcopenia in heart failure: a systematic review and meta‐analysis

AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Zhang, Jia, Ni, Wenqing, Yuan, Xueli, Zhang, Hongmin, Li, Ping, Xu, Jian, Zhao, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006658/
https://www.ncbi.nlm.nih.gov/pubmed/33576177
http://dx.doi.org/10.1002/ehf2.13255
_version_ 1783672349506142208
author Zhang, Yan
Zhang, Jia
Ni, Wenqing
Yuan, Xueli
Zhang, Hongmin
Li, Ping
Xu, Jian
Zhao, Zhiguang
author_facet Zhang, Yan
Zhang, Jia
Ni, Wenqing
Yuan, Xueli
Zhang, Hongmin
Li, Ping
Xu, Jian
Zhao, Zhiguang
author_sort Zhang, Yan
collection PubMed
description AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review and meta‐analysis to estimate the current overall prevalence of sarcopenia in patients with HF. METHODS AND RESULTS: We searched relevant databases for studies published up to 13 July 2020, assessing sarcopenia in vpatients with HF. After careful screening, data of included articles were extracted with a predesigned Excel form. Then the pooled prevalence of sarcopenia in patients with HF was calculated using the random‐effects model. The Q test was used to assess the heterogeneity, and I (2) statistic was calculated to quantify and evaluate the heterogeneity. Subgroup analyses were conducted to determine potential sources of heterogeneity. A total of 2852 articles were initially identified, and after removing duplicate publications and applying the selection criteria, we reviewed 79 full‐text articles. Finally, 11 articles (n = 1742 patients with HF) were included in this systematic review and meta‐analysis. The pooled prevalence of sarcopenia in patients with HF was 34% [95% confidence interval (CI): 22–47%, I (2) = 96.59%] and ranged from 10% to 69%. However, substantial heterogeneity between studies (I (2) = 96.59%, P < 0.001) was observed. There was no significant heterogeneity between subgroups by sex (P = 0.803) or the method used to define sarcopenia (P = 0.307). While the heterogeneity between subgroups by population setting was statistically significant (P < 0.001), the pooled prevalence of sarcopenia was 55% (95% CI: 43–66%) for hospitalized patients with HF and 26% (95% CI: 16–37%) for ambulatory patients. CONCLUSIONS: Sarcopenia was a common condition in patients with HF, and the prevalence of hospitalized patients was higher than for ambulatory patients. Early detection of sarcopenia was therefore important in patients with HF, and it was important to implement interventions so that physical therapists or managerial dieticians can easily be introduced into clinical practice.
format Online
Article
Text
id pubmed-8006658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80066582021-04-01 Sarcopenia in heart failure: a systematic review and meta‐analysis Zhang, Yan Zhang, Jia Ni, Wenqing Yuan, Xueli Zhang, Hongmin Li, Ping Xu, Jian Zhao, Zhiguang ESC Heart Fail Reviews AIMS: Sarcopenia has been found to be frequently associated with co‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review and meta‐analysis to estimate the current overall prevalence of sarcopenia in patients with HF. METHODS AND RESULTS: We searched relevant databases for studies published up to 13 July 2020, assessing sarcopenia in vpatients with HF. After careful screening, data of included articles were extracted with a predesigned Excel form. Then the pooled prevalence of sarcopenia in patients with HF was calculated using the random‐effects model. The Q test was used to assess the heterogeneity, and I (2) statistic was calculated to quantify and evaluate the heterogeneity. Subgroup analyses were conducted to determine potential sources of heterogeneity. A total of 2852 articles were initially identified, and after removing duplicate publications and applying the selection criteria, we reviewed 79 full‐text articles. Finally, 11 articles (n = 1742 patients with HF) were included in this systematic review and meta‐analysis. The pooled prevalence of sarcopenia in patients with HF was 34% [95% confidence interval (CI): 22–47%, I (2) = 96.59%] and ranged from 10% to 69%. However, substantial heterogeneity between studies (I (2) = 96.59%, P < 0.001) was observed. There was no significant heterogeneity between subgroups by sex (P = 0.803) or the method used to define sarcopenia (P = 0.307). While the heterogeneity between subgroups by population setting was statistically significant (P < 0.001), the pooled prevalence of sarcopenia was 55% (95% CI: 43–66%) for hospitalized patients with HF and 26% (95% CI: 16–37%) for ambulatory patients. CONCLUSIONS: Sarcopenia was a common condition in patients with HF, and the prevalence of hospitalized patients was higher than for ambulatory patients. Early detection of sarcopenia was therefore important in patients with HF, and it was important to implement interventions so that physical therapists or managerial dieticians can easily be introduced into clinical practice. John Wiley and Sons Inc. 2021-02-11 /pmc/articles/PMC8006658/ /pubmed/33576177 http://dx.doi.org/10.1002/ehf2.13255 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Zhang, Yan
Zhang, Jia
Ni, Wenqing
Yuan, Xueli
Zhang, Hongmin
Li, Ping
Xu, Jian
Zhao, Zhiguang
Sarcopenia in heart failure: a systematic review and meta‐analysis
title Sarcopenia in heart failure: a systematic review and meta‐analysis
title_full Sarcopenia in heart failure: a systematic review and meta‐analysis
title_fullStr Sarcopenia in heart failure: a systematic review and meta‐analysis
title_full_unstemmed Sarcopenia in heart failure: a systematic review and meta‐analysis
title_short Sarcopenia in heart failure: a systematic review and meta‐analysis
title_sort sarcopenia in heart failure: a systematic review and meta‐analysis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006658/
https://www.ncbi.nlm.nih.gov/pubmed/33576177
http://dx.doi.org/10.1002/ehf2.13255
work_keys_str_mv AT zhangyan sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT zhangjia sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT niwenqing sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT yuanxueli sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT zhanghongmin sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT liping sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT xujian sarcopeniainheartfailureasystematicreviewandmetaanalysis
AT zhaozhiguang sarcopeniainheartfailureasystematicreviewandmetaanalysis